Multispectral Optoacoustic Tomography in Head and Neck Squamous Cell Cancer

Launched by UNIVERSITY OF OKLAHOMA · Jun 20, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating a new imaging technology called Multispectral Optoacoustic Tomography (MSOT) to see how well it can identify and evaluate lymph nodes in the neck that may be affected by head and neck squamous cell cancer. The goal is to determine if this device can provide more accurate information compared to traditional methods, which could help doctors plan better treatments for patients with this type of cancer.

To participate in this study, you need to be at least 18 years old and have been diagnosed with head and neck squamous cell cancer that has spread to the lymph nodes. You must also be willing to give written consent before undergoing the MSOT procedure, and your treatment should be aimed at curing the cancer, not just easing symptoms. Participants will have the opportunity to help advance medical knowledge while receiving careful monitoring throughout the trial. If you're interested, it’s important to know that certain conditions, like having had previous radiation treatment for head and neck cancer or being pregnant, may prevent you from joining.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Clinically confirmed node positive head and neck squamous cell cancer
• • Written informed consent signed and dated by the patient prior to the performance of the MSOT
• • At least 18 years-of-age at the time of signature of the informed consent form (ICF)
• • Patients planned for curative intent therapy
• • Patient available for the study duration
• • Patients of childbearing potential must have a negative pregnancy test prior to the study entry.
• • Patients of childbearing potential must use an effective form of contraceptive as per the protocol.
• Exclusion Criteria:
• • History of previous head and neck radiotherapy
• • Intent of treatment palliative
• • Women who are pregnant
• • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety of efficacy assessment of the investigational regimen should be included.
• • Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol and/or follow-up procedures outlined in the protocol.